Regorafenib for cancer.

@article{Strumberg2012RegorafenibFC,
  title={Regorafenib for cancer.},
  author={Dirk Strumberg and Beate S Schultheis},
  journal={Expert opinion on investigational drugs},
  year={2012},
  volume={21 6},
  pages={879-89}
}
INTRODUCTION Regorafenib (BAY 73-4506) is a novel, orally active, diphenylurea multikinase inhibitor of VEGFR1-3, c-KIT, TIE-2, PDGFR-β, FGFR-1, RET, RAF-1, BRAF and p38 MAP kinase. AREAS COVERED This review covers the preclinical development of regorafenib as well as the pivotal Phase I studies. The safety profile of regorafenib is discussed in context with other oral multikinase inhibitors bearing a similar target profile. Current clinical developments, especially in colorectal cancer (CRC… CONTINUE READING
33 Citations
39 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Analysis of plasma biomarkers, DCE-MRI, and KRAS mutations in patients (pts) with advanced colorectal carcinoma (CRC) treated with the multikinase inhibitor regorafenib [abstract

  • O Christensen, M Buechert, U Fasol
  • Ann Oncol 2010;21(Suppl
  • 2010
Highly Influential
6 Excerpts

Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors [abstract

  • T Shimizu, AW Tolcher, A Patnaik
  • J Clin Oncol 2010;28:3035
  • 2010
Highly Influential
3 Excerpts

An update on the current and emerging targeted agents in metastatic colorectal cancer

  • E. Chu
  • Expert Opin. Investig. Drugs
  • 2012
2 Excerpts

Similar Papers

Loading similar papers…